Genomics

Dataset Information

Phase II Clinical and Immune Correlate Study of Adjuvant Nivolumab plus Ipilimumab for High-Risk Resected Melanoma


ABSTRACT: Phase II Clinical and Immune Correlate Study of Adjuvant Nivolumab plus Ipilimumab for High-Risk Resected Melanoma

PROVIDER: PRJNA907804 | ENA |

REPOSITORIES: ENA